Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BRVE

Braveheart Bio Inc

25.01

Aug 11 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Held by: TMED

Scroll to Statements

Index	-
Market Cap	1.77B
Enterprise Value	1.84B
Income	-
Sales	-
Book/sh	-1.11
Cash/sh	1.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	21.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.11
Current Ratio	8.11
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	45.05%
Insider Trans	38.43%
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.95%
SMA50	-10.95%
SMA200	-10.95%
Trades

Shs Outstand	70.65M
Shs Float	38.83M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	32.00 -21.84%
52W Low	24.61 1.63%
Volatility	- -
ATR (14)	3.37
RSI (14)	-
Beta	-
Rel Volume	0.00
Avg Volume	1.25M
Volume	0

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-17.19%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	25.01
Price	25.01
Change %	0.00%

Aug-07-26 04:05PM

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

(GlobeNewswire) -8.23%

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

M.D.Dr. Travis Murdoch B.S.

Chief Development OfficerMs. Michele Anderson

Chief Scientific OfficerMr. Marc Evanchik M.S.

VP & Head of LegalMs. Natalie Dement J.D.

Director of Corporate DevelopmentMr. Timothy Y. Zhou

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund IV, L.P.	10% Owner	Aug 07 '26	Buy	18.00	1,100,000	19,800,000	10,232,420	Aug 11 05:53 PM
Chimovits Erez	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:31 PM
ORBIMED ADVISORS LLC	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:27 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,920,000	34,560,000	11,640,546	Aug 07 05:25 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,680,000	30,240,000	10,185,478	Aug 07 05:25 PM
Rickey James Paul	Chief Financial Officer	Aug 07 '26	Buy	18.00	27,777	499,986	520,927	Aug 07 04:41 PM
Viehbacher Christopher	Director	Aug 07 '26	Buy	18.00	83,333	1,499,994	609,519	Aug 07 04:31 PM
Malek David I	Director	Aug 07 '26	Buy	18.00	4,166	74,988	533,845	Aug 07 04:31 PM
Anderson Michele A.	Chief Development Officer	Aug 07 '26	Buy	18.00	1,111	19,998	332,161	Aug 07 04:30 PM
Murdoch Travis	CEO and President	Aug 07 '26	Buy	18.00	83,333	1,499,994	2,940,670	Aug 07 04:30 PM
Lubner David Charles	Director	Aug 07 '26	Buy	18.00	55,555	999,990	55,555	Aug 07 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BRVE

Braveheart Bio Inc

Upgrade your Finviz experience